Please use this identifier to cite or link to this item:
Title: The implication of monitoring tumour markers : a personalised medicine approach
Authors: Fava, Charyl
Grech, Louise
Micallef, Rachel
Laspina, Stefan
Barbara, Christopher
Azzopardi, Lilian M.
Keywords: Tumor markers
Pharmaceutical services -- Planning
Cancer -- Patients -- Medical care
Drug monitoring
Pharmacist and patient -- Malta
Personalized medicine -- Malta
Issue Date: 2017-09
Publisher: University of Malta. Department of Pharmacy
Citation: Fava, C., Grech, L., Micallef, R., Laspina, S., Barbara, C., & Azzopardi, L. M. (2017, September). The implication of monitoring tumour markers: a personalised medicine approach. Poster session presented at the 77th FIP Annual Conference, Seoul, Republic of Korea.
Abstract: A poster presentation regarding the implication of monitoring tumour markers: a personalised medicine approach. Introduction: The availability of tumour markers in managing oncology patients contributes to developing personalised pharmacotherapy. The key to successful pharmaceutical care planning depends on the pharmacist being integrated within the multidisciplinary team and a documented system of monitoring drug therapy. Aim: To develop and implement a pharmaceutical personalised approach based on pharmaceutical care plan (PCP) incorporating tumour markers for patients suffering from ovarian, pancreatic or prostate cancer.
Appears in Collections:Scholarly Works - FacM&SPha

Files in This Item:
File Description SizeFormat 
The_implication_of_monitoring_tumour_markers_a_personalised_medicine_approach_2017.pdf865.94 kBAdobe PDFView/Open

Items in OAR@UM are protected by copyright, with all rights reserved, unless otherwise indicated.